NRI PULSE STAFF REPORT
The 2025 edition of TIME100 Most Influential Companies honors leaders and innovators who are transforming industries and tackling some of the world’s most urgent challenges. This year, two Indian American CEOs and one India-based company have made the prestigious list for their groundbreaking contributions in biotech and health-tech.
The 2025 TIME100 Most Influential Companies list was officially published in late June 2025, with coverage appearing online starting June 26, 2025. Additionally, TIME released a special print edition with the list on July 7, 2025.
Dr. Reshma Kewalramani, CEO, Vertex Pharmaceuticals
As the first woman of Indian origin to lead a major American biotech firm, Dr. Reshma Kewalramani continues to make waves at the helm of Boston-based Vertex Pharmaceuticals. In the past year and a half, Vertex has earned FDA approval for Casgevy, the first CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, co-developed with CRISPR Therapeutics.
The company also secured FDA approval for its fifth cystic fibrosis treatment and Journavx, the first non-opioid painkiller approved in over 20 years. Kewalramani credits the company’s success to its strategy of rational drug design—targeting known biological pathways to address diseases with few existing treatments.
“Why did we do this? Because we thought pain was an incredibly important disease where there was no innovation and where we thought we could make a big difference,” she said. Vertex is also working on a cell-based treatment for type 1 diabetes and developing new therapies for chronic kidney disease. With a market cap of $114 billion and double-digit revenue growth, Vertex exemplifies Kewalramani’s vision for “one-and-done curative medicines.”
Sam Kulkarni, CEO, CRISPR Therapeutics
Indian American CEO Sam Kulkarni leads CRISPR Therapeutics, the biotech firm that helped usher in a new era of gene-editing treatments. Following the successful launch of Casgevy, Kulkarni is now focused on extending the use of CRISPR technology to treat more common conditions, including high cholesterol and autoimmune diseases like lupus.
“This marks a shift… that will bring [CRISPR] medicines in a more scalable and affordable manner to patients,” said Kulkarni. His team is working to make these therapies not only medically transformative but also economically accessible. Kulkarni’s leadership is steering CRISPR Therapeutics toward broader impact beyond rare diseases, aiming for equity in genetic medicine.
Prashant Warier, CEO & Co-Founder, Qure.ai
India-based Qure.ai, led by Prashant Warier, is the only Indian-owned company to make this year’s TIME100 list. Founded in Mumbai, the health-tech startup uses deep learning to analyze medical images such as X-rays, CT scans, and ultrasounds, detecting early signs of conditions like tuberculosis, brain trauma, and lung cancer.
“It’s like having a highly-trained assistant that never gets tired and can spot issues immediately,” Warier says. Qure.ai’s AI tools are especially impactful in low-resource settings where radiologists are scarce. With deployments in over 100 countries and 18 FDA clearances—including three in 2024—Qure.ai holds the most FDA approvals for AI-powered lung diagnostics in the U.S.
